New BRCA1 Mutations Found in Black and Hispanic Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

WASHINGTON-Mutations of the BRCA1 gene occur in a different region of the gene among black and Hispanic carriers than in whites and Ash-kenazi Jews, researchers said at the Intercultural Cancer Council’s 7th Biennial Symposium on Minorities, the Medically Underserved, and Cancer.

WASHINGTON—Mutations of the BRCA1 gene occur in a different region of the gene among black and Hispanic carriers than in whites and Ash-kenazi Jews, researchers said at the Intercultural Cancer Council’s 7th Biennial Symposium on Minorities, the Medically Underserved, and Cancer.

BRCA1 mutations in Ashkenazi Jewish women occur most frequently on exon 2, said Jaydutt Vadgama, PhD, director of the molecular oncology program, Charles R. Drew University of Medicine and Science, Los Angeles. The mutation known as 185del AG is predominant in this group, he said. Another mutation found in Ashkenazis is 5382ins C, which is also found in non-Ashkenazi whites.

In a study at Drew University, none of 54 black breast cancer patients or 47 Hispanic breast cancer patients had these mutations, Dr. Vadgama and co-researcher Dejun Shen, PhD, reported. They did, however, have mutations on exon 11.

In four black patients, there was a sequence variant labeled A3537G, and in another black woman, a frameshift mutation identified as 3331ins G was found. A novel mutation identified as C3717T was discovered in a Hispanic patient.

Several other sequence variants, polymorphism, and frameshift and nonsense irregularities were revealed as well.

Dr. Vadgama said that further work must be done to identify the significance of these mutations in relation to incidence and course of disease. The mutation identified in the Hispanic woman is the first BRCA1 mutation to be specifically attributed to that ethnic group. However, it is possible that this mutation and the others seen in the study might be found in other groups.

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
3 experts in this video
Related Content